Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. (2021)
Attributed to:
Peptide conjugated oligonucleotides for a phase I/IIa clinical trial in Spinal Muscular Atrophy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1172/jci.insight.149446
PubMed Identifier: 34236053
Publication URI: http://europepmc.org/abstract/MED/34236053
Type: Journal Article/Review
Volume: 6
Parent Publication: JCI insight
Issue: 13
ISSN: 2379-3708